Drug Trial Radar · NCT07621237
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jun 25, 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Tonix Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests
Conditions
- Major Depressive Episode (MDE)
- Major Depressive Disorder (MDD)
- Depression
Interventions
TNX-102 SLDrug
Participants will take 5.6 mg of TNX-102 SL ( 2 x 2.8 mg TNX-102 SL tablets) daily at bedtime.
Placebo sublingual tabletDrug
Participants will take placebo ( 2 x placebo sublingual tablets) daily at bedtime.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline (Visit 2) in the MADRS total score at Week 6.Time frame: From Day 1 to Week 6
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Phoenix, Arizona · Recruiting
Clinical Research Site
Buena Park, California · Recruiting
Clinical Research Site
Chino, California · Recruiting
Clinical Research Site
Lemon Grove, California · Recruiting
Clinical Research Site
Orange, California · Recruiting
Clinical Research Site
San Diego, California · Recruiting
Clinical Research Site
Walnut Creek, California · Recruiting
Clinical Research Site
Jacksonville, Florida · Recruiting
Clinical Research Site
Maitland, Florida · Recruiting
Clinical Research Site
Miami, Florida · Recruiting
Clinical Research Site
Orange City, Florida · Recruiting
Clinical Research Site
Orlando, Florida · Recruiting
Clinical Research Site
Tampa, Florida · Recruiting
Clinical Research Site
Norcross, Georgia · Recruiting
Clinical Research Site
Chicago, Illinois · Recruiting
Clinical Research Site
New Orleans, Louisiana · Withdrawn
Clinical Research Site
Rockville, Maryland · Recruiting
Clinical Research Site
Methuen, Massachusetts · Recruiting
Clinical Research Site
Las Vegas, Nevada · Recruiting
Clinical Research Site
New York, New York · Recruiting
Clinical Research Site
North Charleston, South Carolina · Recruiting
Clinical Research Site
Mephis, Tennessee · Recruiting
Clinical Research Site
Austin, Texas · Recruiting
Clinical Research Site
Dallas, Texas · Recruiting
Clinical Research Site
McKinney, Texas · Recruiting
Clinical Research Site
Plano, Texas · Recruiting
Clinical Research Site
Provo, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.